

Correction: *Insights from immuno-oncology: the Society for Immunotherapy of Cancer Statement on access to IL-6-targeting therapies for COVID-19*

Ascierto PA, Fox B, Urba W, *et al.* Insights from immuno-oncology: the Society for Immunotherapy of Cancer Statement on access to IL-6-targeting therapies for COVID-19. *J Immunother Cancer*. 2020;8:e000878. doi: 10.1136/jitc-2020-000878

Since the online publication of this article, the authors have noticed the following errors:

1) The following authors were missing the middle initial in their name; Bernard A Fox, Walter J Urba, Julie R Brahmer, Daniel S Chen, Tanja D de Gruijl, F Stephen Hodi Jr, Howard L Kaufman, Michael T Lotze, Kim M Margolin, Francesco M Marincola. The author name Jon M Wigginton was also spelt incorrectly as Jon M Wiggington. The author list is shown below and has been updated in the article.

Paolo Antonio Ascierto,¹ Bernard A Fox,² Walter J Urba,² Ana Carrizosa Anderson,³ Michael B Atkins,⁴ Ernest C Borden,⁵ Julie R Brahmer,⁶ Lisa H Butterfield,⁷ Alessandra Cesano,⁸ Daniel S Chen,⁹ Tanja D de Gruijl,¹⁰ Robert O Dillman,¹¹ Charles G Drake,¹² Leisha A Emens,¹³ Thomas F Gajewski,¹⁴ James L Gulley,¹⁵ F Stephen Hodi Jr,¹⁶ Patrick Hwu,¹⁷ David Kaufman,¹⁸ Howard L Kaufman,¹⁹ Michael T Lotze,²⁰ Douglas G McNeel,²¹ Kim A Margolin,²² Francesco M Marincola,²³ Michael J Mastrangelo,²⁴ Marcela V Maus,²⁵ David R Parkinson,²⁶ Pedro J Romero,²⁷ Paul M Sondel,²⁸ Stefani Spranger,²⁹ Mario Sznol,³⁰ George J Weiner,³¹ Jon M Wigginton,³² Jeffrey S Weber³³

2) Affiliations 1, 2, 3, 4, 5, 11, 14, 15, 16, 20, 21, 22, 26, 28 were incorrect and affiliations 8, 32, 34 have been removed. The updated affiliation list is shown below and has been updated in the article.

¹Istituto Nazionale Tumori IRCCS Fondazione 'G. Pascale', Naples, Italy

²Earle A. Chiles Research Institute, Providence Cancer Institute, Portland, Oregon, USA

³Harvard Medical School, Boston, Massachusetts, USA

⁴Georgetown Lombardi Comprehensive Cancer Center, Washington DC, USA

⁵University of Wisconsin Clinical Cancer Center, Madison, Wisconsin, USA

⁶Johns Hopkins University School of Medicine, Sidney Kimmel Comprehensive Cancer Center, Baltimore, Maryland, USA

⁷Research, Parker Institute for Cancer Immunotherapy, San Francisco, California, USA

⁸ESSA Pharma Inc, Redwood City, California, USA

⁹IGM Biosciences Inc, Mountain View, California, USA

¹⁰Medical Oncology - Amsterdam University Medical Centers, Vrije Universiteit-Cancer Center Amsterdam, Amsterdam, The Netherlands

¹¹AIVITA Biomedical, Inc, Irvine, California, USA

¹²Herbert Irving Comprehensive Cancer Center, Columbia University Medical Center, New York, New York, USA

¹³UPMC Hillman Cancer Center, Pittsburgh, Pennsylvania, USA

¹⁴Pathology and Medicine, Immunology and Cancer Program, University of Chicago, Chicago, Illinois, USA

¹⁵National Cancer Institute, Bethesda, Maryland, USA

¹⁶Dana Farber Cancer Institute, Boston, Massachusetts, USA

¹⁷University of Texas MD Anderson Cancer Center, Houston, Texas, USA

¹⁸Bill & Melinda Gates Medical Research Institute, Cambridge, Massachusetts, USA

¹⁹Immuneering Corp New York, New York, New York, USA

²⁰University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania, USA

²¹Carbone Cancer Center, University of Wisconsin-Madison, Madison, Wisconsin, USA

²²Medical Oncology, City of Hope National Medical Center, Duarte, California, USA

²³Refuge Biotechnologies, Menlo Park, California, USA

²⁴Thomas Jefferson Medical College, Philadelphia, Pennsylvania, USA

²⁵Massachusetts General Hospital Cancer Center, Harvard Medical School, Massachusetts General Hospital, Boston, Massachusetts, USA



²⁶ESSA Pharma Inc, Palo Alto, California, USA

²⁷Oncology, University of Lausanne, Lausanne, VD, Switzerland

²⁸Pediatrics, University of Wisconsin Madison, Madison, Wisconsin, USA

²⁹Massachusetts Institute of Technology Koch Institute for Integrative Cancer Research, Cambridge, Massachusetts, USA

³⁰Yale Cancer Center, Yale School of Medicine, New Haven, Connecticut, USA

³¹Holden Comprehensive Cancer Center, The University of Iowa, Iowa City, Iowa, USA

³²MacroGenics Inc, Rockville, Maryland, USA

³³Laura and Isaac Perlmutter Comprehensive Cancer Center, NYU Langone Medical Center, New York, New York, USA

3) In the main text,

- ▶ The sentence ‘The hypoxia and profound inflammatory response associated with the pneumonitis observed with the severe acute respiratory virus coronavirus-2 SARS-COV-2 virus...’ now reads ‘The hypoxia and profound inflammatory response associated with the pneumonitis observed with the SARS-CoV-2 virus...’
- ▶ The sentence ‘One possibility is to encourage the use of IL-6 or IL-6-receptor (IL-6R) blocking antibodies like tocilizumab (Actemra, Roche-Genentech), sarilumab (Kevzara, Regeneron) and siltuximab (Sylvant, EUSA Pharma)...’ now reads ‘One possibility is to encourage the use of IL-6 or IL-6-receptor (IL-6R) blocking antibodies like tocilizumab (ActemraTM, Roche-Genentech), sarilumab (KevzaraTM, Regeneron) and siltuximab (SylvantTM, EUSA Pharma)...’
- ▶ The sentence ‘...including tocilizumab and sarilumab for use on a compassionate basis to critically ill hospitalized COVID-19-infected patients during this extraordinary situation’ now reads ‘...including tocilizumab and sarilumab for use on a compassionate basis to critically ill hospitalized SARS-CoV-2-infected patients during this extraordinary situation’

4) To acknowledge medical writing support, the acknowledgment section has been updated to read:

‘The authors thank the clinicians working tirelessly on the frontlines of the COVID-19 pandemic. The authors also acknowledge SITC staff for their contributions including Sam Million Weaver, PhD for medical writing and editorial support and Angela Kilbert for project management and assistance. Additionally, the authors wish to thank the society for supporting the manuscript development.’

5) In the competing interests section:

- ▶ Bristol-Myers Squibb was spelt incorrectly as ‘Bristol-Myer Squibb’ and ‘Bristol-Myers-Squibb’
- ▶ The initials for authors BF, JB, ACA, DC, TdG. HK, ML, FM, KM now read BAF, JRB, AC, DSC, TDG, HLK, MTL, FMM, KAM

Open access This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, appropriate credit is given, any changes made indicated, and the use is non-commercial. See <http://creativecommons.org/licenses/by-nc/4.0/>.

© Author(s) (or their employer(s)) 2020. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ.

J Immunother Cancer 2020;**13**:e000878corr1. doi:10.1136/jitc-2020-000878corr1

